Table 1.

Patient profile. Clinical, molecular, and spectroscopic characteristics of patients with new and recurrent LrGG

Tumor classification	Patients (%)
LrGG (n = 45)
Male/Female	27/18 (60/40%)
Grade 2/3	30/15 (67/33%)
Newly diagnosed	40 (89%)
Recurrent	5 (11%)
IDH+ glioma (n = 42)
Grade 2/3	29/13 (69/31%)
Oligodendroglioma	16 (38%)
Astrocytoma	26 (62%)
p53+ (n = 31/37)
2HG quantifiable	39 (93%)
IDH− glioma (n = 3)
Grade 2/3	1/2 (33/67%)
Oligodendroglioma	0 (0%)
Astrocytoma	3 (100%)
p53+ (n = 1/2)
2HG quantifiable	1 (33%)